Current trials using bone-targeting agents in prostate cancer

Cancer Journal

Volumn 14, Issue 1, 2008, Pages 35-39

  Tu, Shi Ming ^a   Lin, Sue Hwa ^a  

^a UNIVERSITY OF TEXAS   (United States)

Author keywords

Bone metastasis; Prostate cancer

Indexed keywords

AFLIBERCEPT; ATRASENTAN; BEVACIZUMAB; CALCITRIOL; CEDIRANIB; CHEMOKINE RECEPTOR CXCR4; CILENGITIDE; CNTO 328; CP 751871; DASATINIB; DENOSUMAB; DOCETAXEL; DOXORUBICIN; ED 4045; ENDOTHELIN 1; ENDOTHELIN A RECEPTOR ANTAGONIST; ESTRAMUSTINE; IMATINIB; KETOCONAZOLE; KX 239; LENALIDOMIDE; MSX 122; PLERIXAFOR; PREDNISONE; R 04858696; SAMARIUM 153; SOMATOMEDIN; STRONTIUM 89; SUNITINIB; TANDUTINIB; THALIDOMIDE; UNCLASSIFIED DRUG; UNINDEXED DRUG; VINBLASTINE; ZD 4045; ZOLEDRONIC ACID; ANGIOGENESIS INHIBITOR; ANTINEOPLASTIC AGENT; BISPHOSPHONIC ACID DERIVATIVE; CXCR4 PROTEIN, HUMAN; DRUG DERIVATIVE; PLATELET DERIVED GROWTH FACTOR; RADIOPHARMACEUTICAL AGENT; VITAMIN D;

BONE METASTASIS; CANCER COMBINATION CHEMOTHERAPY; CANCER GROWTH; CANCER RADIOTHERAPY; CANCER STEM CELL; CELL SURVIVAL; CLINICAL TRIAL; ENDOTHELIUM CELL; HUMAN; NONHUMAN; OSTEOBLAST; PRIORITY JOURNAL; PROSTATE CANCER; REVIEW; BONE TUMOR; DRUG EFFECT; MALE; METASTASIS; OSTEOCLAST; PATHOLOGY; PATHOPHYSIOLOGY; PROSTATE TUMOR;

ANGIOGENESIS INHIBITORS; ANTINEOPLASTIC AGENTS; BONE NEOPLASMS; CLINICAL TRIALS AS TOPIC; DIPHOSPHONATES; ENDOTHELIN-1; HUMANS; MALE; OSTEOBLASTS; OSTEOCLASTS; PLATELET-DERIVED GROWTH FACTOR; PROSTATIC NEOPLASMS; RADIOPHARMACEUTICALS; RECEPTORS, CXCR4; SOMATOMEDINS; VITAMIN D;

EID: 43049170371     PISSN: 15289117     EISSN: 1540336X     Source Type: Journal    
DOI: 10.1097/PPO.0b013e318161d32d     Document Type: Review

References (34)

1. Adams GB, Scadden DT. The hematopoietic stem cell in its place. Nat Immunol. 2006;7:333-337.
2. Blake GM, Zivanovic MA, Blaquiere RM, et al. Strontium-89 therapy: measurement of absorbed dose to skeletal metastases. J Nucl Med. 1988;29:549-657.
3. Porter AT, McEwan AJB, Powe JE, et al. Results of a randomized phase III trial to evaluate the efficacy of strontium-89 adjuvant to local field external beam irradiation in the management of endocrine resistant metastatic prostate cancer. Int J Radiat Oncol Biol Phys. 1993;25:805-813.
4. Tu SM, Millikan RE, Mengistu B, et al. Bone-targeted therapy for advanced androgen-independent carcinoma of the prostate: a randomized phase II trial. Lancet. 2001;357:336-341.
5. Tu SM, Kim J, Pagliaro LC, et al. Therapy tolerance in selected patients with androgen-independent prostate cancer following strontium-89 combined with chemotherapy. J Clin Oncol. 2005;23:7904-7910.
6. Takuwa Y, Masaki T, Yamashita K. The effects of the endothelin family peptides on cultured osteoblastic cells from rat calvariae. Biochem Biophys Res Commun. 1990;170:998-1005.
7. Carducci MA, Saad F, Abrahamsson P-A, et al. A phase 3 randomized controlled trial of the efficacy and safety of atrasentan in men with metastatic hormone-refractory prostate cancer. Cancer. 2007;110:1959-1966.
8. James ND. ZD4054, a potent, specific endothelin A receptor antagonist, improves overall survival in pain-free or mildly symptomatic patients with hormone-resistant prostate cancer and bone metastasis. Paper presented at the 14th European Cancer Conference; September 23-27, 2007; Barcelona, Spain. Abstract 3LB.
9. Beer TM, Ryan CW, Venner PM, et al. Double-blinded randomized study of high-dose calcitriol plus docetaxel compared with placebo plus docetaxel in androgen-independent prostate cancer: a report from the Ascent investigators. J Clin Oncol. 2007;25:669-74.
10. 3 growth inhibition in the LNCaP prostate cancer cell line through p21/WAF1 J Urol. 2001;165: 1319-1324.
11. Koutsilieris M, Reyes-Moreno C, Sourla A, et al. Growth factors mediate glucocorticoid receptor function and dexamethasone-induced regression of osteoblastic lesions in hormone refractory prostate cancer. Anticancer Res. 1997;17:1461-1466.
12. Costa L, Demers LM, Gouveia-Oliveira A, et al. Prospective evaluation of the peptide-bound collagen type I cross-links N-telopeptide and C-telopeptide in predicting bone metastases status. J Clin Oncol. 2002; 20:850-856.
13. Michaelson MD, Marujo RM, Smith MR. Contribution of androgen deprivation therapy to elevated osteoclast activity in men with metastatic prostate cancer. Clin Cancer Res. 2004;10:2705-2708.
14. Rogers MJ, Gordon S, Benford HL, et al. Cellular and molecular mechanisms of action of bisphosphonates. Cancer. 2000;88:2961-2978.
15. Saad F, Gleason DM, Murray R, et al. Long-term efficacy of zoledronic acid for the prevention of skeletal complications in patients with metastatic hormone-refractory prostate cancer. J Natl Cancer Inst. 2004;96: 879-882.
16. Major PP, Cook R, Chen B, et al. Zoledronic acid reduces the survivaladjusted cumulative incidence of radiation to bone and skeletal complications in patients with advanced prostate cancer. Paper presented at the Multidisciplinary Prostate Cancer Symposium; February 17-19, 2005; Orlando, Florida. Abstract 282.
17. Small EJ, Smith MR, Seaman JJ, et al. Combined analysis of two multicenter, randomized, placebo-controlled studies of pamidronate disodium for the palliation of bone pain in men with metastatic prostate cancer. J Clin Oncol. 2003;21:4277-4284.
18. Ernst DS, Tannock IF, Winquist EW, at al. Randomized, double-blind, controlled trial of mitoxantrone/prednisone and clodronate versus mitoxantrone/prednisone and placebo in patients with hormone-refractory prostate cancer and pain. J Clin Oncol. 2003;21:3335-3342.
19. Lewiecki EM. RANK ligand inhibition with denosumab for the management of osteoporosis. Expert Opin Biol Ther. 2006;6:1041-1050.
20. Chang YM, Kung HJ, Evans CP. Nonreceptor tyrosine kinases in prostate cancer. Neoplasia. 2007;9:90-100.
21. Nam S, Kim D, Cheng JQ, et al. Action of the Src family kinase inhibitor, dasatinib (BMS-354825), on human prostate cancer cells. Cancer Res. 2005;65:9185-9189.
22. Tu SM, Lin SH, Logothetis CJ. Stem-cell origin of metastasis and heterogeneity in solid tumors. Lancet Oncol. 2002;3:508-13.
23. Calabrese C, Poppleton H, Kocak M, et al. A perivascular niche for brain tumor stem cells. Cancer Cell. 2007;11:69-82.
24. Duque JL, Loughlin KR, Adam RM, et al. Plasma levels of vascular endothelial growth factor are increased in patients with metastatic prostate cancer. Urology. 1999;54:523-527.
25. Weidner N, Carroll PR, Flax J, et al. Tumor angiogenesis correlates with metastasis in invasive prostate carcinoma. Am J Pathol. 1993;143:401-409.
26. Reese D, Frohlich, M, Bok R, et al. A phase II trial of humanized monoclonal anti-vascular endothelial growth factor antibody (rhuMAb VEGF) in hormone refractory prostate cancer. Proc Am Soc Clin Oncol. 1999;18:351.
27. Picus J, Halabi S, Rini B, et al. The use of bevacizumab with docetaxel and estramustine in hormone-refractory prostate cancer: initial results of CALGB 90006. Proc Am Soc Clin Oncol. 2003;22:393.
28. Geitz H, Handt S, Zwingenberger K. Thalidomide selectively modulates the density of cell surface molecules involved in the adhesion cascade. Immunopharmacology. 1996;31:213-221.
29. Corral LG, Haslett PA, Muller GW, et al. Differential cytokine modulation and T cell activation by two distinct classes of thalidomide analogues that are potent inhibitors of TNF-α. J Immunol. 1999;163: 380-386.
30. Dahut WL, Gulley JL, Arlen PM, et al. Randomized phase II trial of docetaxel plus thalidomide in androgen-independent prostate cancer. J Clin Oncol. 2004;22:2532-2539.
31. Chott A, Sun Z, Morganstern D, et al. Tyrosine kinases expressed in vivo by human prostate cancer bone marrow metastases and loss of the type 1 insulin-like growth factor receptor. Am J Pathol. 1999;155:1271-1279.
32. Ko YJ, Small EJ, Kabbinavar F, et al. A multi-institutional phase II study of SU101, a platelet-derived growth factor receptor inhibitor, for patients with hormone-refractory prostate cancer. Clin Cancer Res. 2001;7:800-805.
33. Uehara H, Kim SJ, Karashima T, et al. Effects of blocking plateletderived growth factor-receptor signaling in a mouse model of experimental prostate cancer bone metastases. J Natl Cancer Inst. 2003;95: 458-570.
34. Mathew P, Thall PF, Bucana CD, et al. Platelet-derived growth factor receptor inhibition and chemotherapy for castration-resistant prostate cancer with bone metastasis. Clin Cancer Res. 2007;13:5816-5824.